With 100% potential to penetrate the blood-brain barrier

According to the latest announcement from the Center for Drug Evaluation (CDE) of the State Drug Administration of China, the first class of new drug zorifertinib tablets declared by Chentai Pharmaceutical has obtained the implied license for clinical trials, and it is planned to be developed for the treatment of non-small cell lung cancer (NSCLC)

Chentai Pharmaceutical was established in 2017 and is committed to the clinical development of innovative drugs worldwide

Brain metastasis is the main treatment problem for EGFR mutation-positive advanced non-small cell lung cancer.

According to information on Chentai Pharmaceutical's official website, as a new generation of EGFR-TKI, zorifertinib has a strong blood-brain barrier penetration ability, which can penetrate 100% of the blood-brain barrier, and can reach drugs similar to those in plasma in the cerebrospinal fluid and brain tissue.

Previously, zorifertinib has explored the dose safety and clinical indications of the candidate drug in a phase 1 clinical study called BLOOM

In terms of survival data, the median progression-free survival (PFS) of patients with EGFR-TKI-naïve brain metastases treated with zorifertinib can reach about 14 months

Based on the positive clinical efficacy of the BLOOM study in patients with meningeal metastases, zorifertinib started the EVEREST (AZD3759-003) phase 2/3 randomized controlled clinical trial in April 2018

references:

[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.

[2] The expert advisory meeting of Chentai Pharmaceutical's research drug Zorifertinib was held in Shanghai.